Table 3 Treatment options after second-generation ALK-TKI resistance in the real world
Cohort 1 n = 20 13 dead | Cohort 2 n = 53 28 dead | All populations n = 73 41 dead | |
|---|---|---|---|
≥ 1 line of subsequent treatment | |||
Yes No | 18 (90%) 2 (10%) | 48 (90.6%) 5 (9.4%) | 66 (90.4%) 7 (9.6%) |
≥ 1 line of subsequent ALK-TKI | |||
Yes No | 17 (85%) 3 (15%) | 44 (83.0%) 9 (17.0%) | 61 (83.6%) 12 (16.4%) |
Subsequent third-generation ALK-TKI | |||
Yes No | 11 (55%) 9 (45%) | 29 (54.7%) 24 (45.3%) | 40 (54.8%) 33 (45.2%) |
≥ 1 line of chemotherapy | |||
Yes No | 12 (60%) 8 (40%) | 23 (43.4%) 30 (56.6%) | 35 (47.9%) 38 (52.1%) |
≥ 1 line of chemotherapy in dead group | |||
Yes No | 8 (61.5%) 5 (38.5%) | 15 (53.6%) 13 (46.4%) | 23 (56.1%) 18 (43.9%) |